Ziv-aflibercept in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program (ASQoP and AFEQT studies) in patients ≥65.Roberto Bordonaro, David Ferry, Emmanuelle Dochy et al.|Journal of Clinical Oncology|2014Cited by 8
Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program in pts pretreated with bevacizumab (B).David Ferry, Gérard Lledo, Alberto F. Sobrero et al.|Journal of Clinical Oncology|2014Cited by 3
Quality of life maintained on the ziv-aflibercept/FOLFIRI regimen: Third interim analysis of the global aflibercept safety and HR-QOL program.Julien Taı̈eb, Alberto F. Sobrero, Roberto Bordonaro et al.|Journal of Clinical Oncology|2014Cited by 1
Ziv-aflibercept in combination with FOLFIRI for the second-line treatment of patients with metastatic colorectal cancer: Third interim safety data from the global aflibercept safety and quality-of-life program (ASQoP and AFEQT studies).Roberto Bordonaro, Julien Taı̈eb, Alberto F. Sobrero et al.|Journal of Clinical Oncology|2014Cited by 0